[Letter to Daniel K. Inouye from the Intramural Members of NIH/FDA gp160 Advisory Panel]

SENT BY: XEROX Telecopier 7017; 9-30-93; 9:02; 2129515381-+ 4153910513;3
WMMX. +. i 1Lff WK t P U NU.,FUN PAGE i3
Septembr 27, 1993
senator Daniel Ks Inouye
chairman
Defense Appropriations Subcommittee
0.S. senate
NMI Conisensugsstatement of IntramuLral members of
the NIX/FDA gplo Advisory Panel
Dear chairman Inouye:Z
As researchers and AIDS advocates who served on the tNI1/FDA gpl6O
advisory panel, we rind that the scientific evidence to date does
not yet justify Federal support for a large phase III study of
either one or several candidate HIV therapeutic vaccines. We
therefore recommend that the Congress clarify its legislative
intent to allow the Army to distribute the $20 million
appropriation from fall 1992 in a program of investigatorinitiated AIDS research grants awarded under the guidance of an
expert, objective peer review committee to be commissioned by the
Department of Defense. We recommend further that these awards be
open to basic, clinical, therapeutic, vaccine, arid behavioral
AIDS researchers without further limitation. In the event that
new scientific evidence emerges to support a large-scale clinical
trial of HIV therapeutic vaccines, we recommended public funds be
prohibited from being spent on purchasing vaccine for such a
trial, and that the total publ.ically supported cost of such a
trial not exceed $20 million,
Yours twruly,
Charles C.J. Carpenter, M.D.

Meo~s Agoito sSVned In op we of Anita D. TeyLor, wh~o has tuft relic.
111111 IIVIIIIIIIIIIIII1IIIIQIIIIII
5571095.0446.001.".. w.,r.....